Advertisement
YOU ARE HERE: LAT HomeCollectionsRoche Holdings Ltd
IN THE NEWS

Roche Holdings Ltd

FEATURED ARTICLES
BUSINESS
May 3, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Syntex Corp., a pioneering Silicon Valley company that lately has fallen on hard times, has agreed to be acquired by Switzerland's Roche Holdings Ltd. in a $5.3-billion deal that would create the world's fourth-largest drug company. The merger, one of the largest ever between drug makers, comes as the pharmaceutical industry attempts to cope with health reform and intense pressure from government, health maintenance organizations and hospital groups to cut prices.
ARTICLES BY DATE
BUSINESS
May 3, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Syntex Corp., a pioneering Silicon Valley company that lately has fallen on hard times, has agreed to be acquired by Switzerland's Roche Holdings Ltd. in a $5.3-billion deal that would create the world's fourth-largest drug company. The merger, one of the largest ever between drug makers, comes as the pharmaceutical industry attempts to cope with health reform and intense pressure from government, health maintenance organizations and hospital groups to cut prices.
Advertisement
BUSINESS
June 4, 1999 | PAUL JACOBS, TIMES STAFF WRITER
Roche Holdings Ltd. said Thursday that it will exercise its option to buy the outstanding shares in Genentech for $4.2 billion, but has decided to allow the South San Francisco biotechnology company to continue operating independently. The Swiss-based pharmaceutical company, which already owns 65% of Genentech stock, will pay $82.50 a share for the remaining shares. Then, if regulators approve the deal, it will raise more than $2 billion by selling up to 19% of the company back to the public.
BUSINESS
April 12, 2001 | DENISE GELLENE, TIMES STAFF WRITER
Amgen Inc. on Wednesday won a patent infringement lawsuit in the United Kingdom over its blockbuster anti-anemia drug, Epogen. The ruling should ease the June debut of Amgen's widely anticipated successor to Epogen. The British High Court of Justice ruled that Transkaryotic Therapies Inc. and Roche Holdings Ltd. infringed on Amgen's patent on erythropoietin, a protein that spurs production of red blood cells. Transkaryotic said it will appeal. The Cambridge, Mass.
BUSINESS
August 21, 1990 | MARJORIE SHAFFER, REUTERS
Biotechnology stocks are shining after years of volatility and some big setbacks. Although plenty of roadblocks still lie ahead, there are more products nearing the market and more investor money is pouring in, prompting analysts to say the once-fledgling industry has at last come of age. Over the last 6 months, some biotechnology stocks have more than doubled in value, and the biggest companies have jumped nearly 50% in value.
BUSINESS
May 3, 1994 | From Times Staff and Wire Reports
A drug industry megamerger helped the stock market rally Monday despite a jump in interest rates--the second consecutive session in which stocks have ignored the bond market's troubles. Meanwhile, the stumbling dollar continued to lose ground against the German mark, but stabilized against the Japanese yen. On Wall Street, the Dow Jones industrials gained 19.33 points to 3,701.02, as health-care issues jumped following news that drug maker Syntex agreed to a $5.
BUSINESS
April 28, 1992 | SUSAN CHRISTIAN, TIMES STAFF WRITER
They were the born-agains of the corporate world--California companies that bounced back to life in 1991 after posting big losses just one year before. Reasons for the turnarounds are as varied as the companies themselves. Occidental Petroleum Corp., which made the biggest comeback, reported a big loss in 1990 while undergoing an aggressive restructuring that quickly paid off.
Los Angeles Times Articles
|